| Long name: |
Cy3 Conjugated, DPYD Polyclonal Antibody |
| Category: |
Conjugated Primary Antibodies |
| Conjugation: |
cy3 conjugation kit |
| Host Organism: |
Rabbit (Oryctolagus cuniculus) |
| Target Antigen: |
DPYD |
| Specificity: |
This is a highly specific antibody against DPYD |
| Modification: |
Unmodified |
| Modification site: |
None |
| Clonality: |
Polyclonal |
| Clone: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Source: |
KLH conjugated synthetic peptide derived from human DPYD |
| Gene ID number: |
1806 |
| Tested applications: |
IF(IHC-P) |
| Recommended dilutions: |
IF(IHC-P)(1:50-200) |
| Crossreactivity: |
Mouse, Rat, Human |
| Crossreactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Antigen background: |
Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs, DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU, DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU, Leukopenia, Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil, Specifically, This reaction includes stomatitis, Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene, a deficiency of DPYD leads to an accumulation of uracil and thymine, also known as hereditary thymine-uraciluria or familial pyrimidinemia, and neurologic symptoms, cerebellar ataxia, diarrhea, fever, hair loss, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression, marked weight loss, progressing to semicoma, thrombocytopenia, thus, thymine and 5-hydroxymethyluracil, Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine, Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA |
| Excitation Emission: |
512, 550nm/570, 615nm |
| Synonyms: |
DPD |
| Properties: |
1 of the DPYD Antibody, Conjugated can be used in flow cytometry but typically shows lower fluorescence intensity comparable to that of PE or APC, Cy3 antibodies are excited by the 488-nanometer wave of an argon laser and the 633-nanometer line of a helium-neon diode laser, This Bioss Primary Conjugated Antibodies antibody is well suited for fluorescent microscopy, C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
DPYD Conjugated |
| Short name: |
Conjugated, DPYD Antibody |
| Technique: |
antibodies against human proteins, antibodies for, antibody Conjugates, Antibody |
| Label: |
Cy3 |
| Alternative name: |
cyanine 3 coupled, DPYD (Antibody to) |
| Alternative technique: |
antibodies |
| Identity: |
3012 |
| Gene: |
DPYD |
More about : DPYD |
| Long gene name: |
dihydropyrimidine dehydrogenase |
| Locus: |
1p21, 3 |
| Discovery year: |
1994-07-07 |
| GenBank acession: |
U20938 |
| Entrez gene record: |
1806 |
| Pubmed identfication: |
7713523 |
| RefSeq identity: |
NM_000110 |
| Havana BLAST/BLAT: |
OTTHUMG00000039683 |
| Locus Specific Databases: |
UMD Locus Specific Databases LRG_722 |